Thumbnail
Access Restriction
Subscribed

Author Kong, Wen Tao ♦ Yuan, Hai Xia ♦ Cai, Hao ♦ Wang, Wen Ping ♦ Tang, Yang ♦ Zhang, Xiao Long
Source SpringerLink
Content type Text
Publisher Springer Netherlands
File Format PDF
Copyright Year ©2014
Language English
Subject Domain (in DDC) Technology ♦ Medicine & health
Subject Keyword Contrast-enhanced ultrasound ♦ VX2 liver tumor model ♦ Sorafenib ♦ Enhancement pattern ♦ Quantification analysis ♦ Cancer Research
Abstract The aim of our study was to investigate the application of contrast-enhanced ultrasound (CEUS) and its quantification analysis for the prediction of early treatment response of sorafenib on rabbit VX2 liver tumor model. Rabbits were implanted VX2 tumor mass to establish a liver tumor model. Fourteen days after tumor implantation, rabbits presented with single liver tumor were randomly divided into two groups. Rabbits in treatment group were given by gavage once a day for 14 days with sorafenib suspension at a dose of 30 mg/kg, whereas rabbits in control group were given saline by gavage of the same volume. CEUS was performed before treatment and 3, 7, 14 days after treatment for the analysis of tumor size, enhancement pattern, and necrosis range. The time intensity curve (TIC) was used to obtain quantitative parameters of enhancement patterns. Before sorafenib administration, tumor volumes ranged from 0.24 to 0.75 cm$^{3}$ (mean 0.49 ± 0.18 cm$^{3}$) in treatment group and 0.24 to 0.44 cm$^{3}$ (mean 0.30 ± 0.12 cm$^{3}$) in control group. The dynamic enhancement patterns of tumors were homogeneous hyper-enhancement (n = 8), heterogeneous hyper-enhancement (n = 4), and peripheral rim-like enhancement (n = 2). All tumors of the treatment group presented with peripheral rim-like enhancement with large necrotic area after sorafenib administration, whereas tumors of the control group showed heterogeneous hyper-enhancement (n = 5) and peripheral rim-like enhancement (n = 2). There was a significant difference in area under the curve (AUC) before and after sorafenib treatment (P = 0.045). CEUS may be of value in the evaluation of early therapeutic response after sorafenib administration.
ISSN 10104283
Age Range 18 to 22 years ♦ above 22 year
Educational Use Research
Education Level UG and PG
Learning Resource Type Article
Publisher Date 2014-12-02
Publisher Place Dordrecht
e-ISSN 14230380
Journal Tumor Biology
Volume Number 36
Issue Number 4
Page Count 7
Starting Page 2593
Ending Page 2599


Open content in new tab

   Open content in new tab
Source: SpringerLink